Close

Minerva Neurosciences (NERV) Announces MIN-101 Phase 2b Met Primary Endpoint in Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/26/2024

1. META
2. GOOGL
3. CMG
4. MSFT
5. LRCX
6. IBM
7. SPY
8. INTC
9. SNAP
10. BA


Go back to Minerva Neurosciences (NERV) Announces MIN-101 Phase 2b Met Primary Endpoint in Schizophrenia
(NASDAQ: NERV) Delayed: 2.43 --0 (-0%)
Previous Close $2.43    52 Week High $15.84 
Open $2.43    52 Week Low $3.45 
Day High $2.43    P/E N/A 
Day Low $2.43    EPS $0.00 
Volume 460